Dynavax Technologies Corporation announced that Francis R. Cano, Ph.D. has been appointed to Dynavax's Board of Directors effective November 3, 2009. Francis brings unique expertise and broad experience in research, development, and commercialization to Dynavax. Francis will provide valuable perspective as Dynavax advances its plans for its Phase 3 hepatitis B vaccine and pipeline products. Dr. Cano is President and Founder of Cano Biotech Corp.

Dynavax Technologies Corporation announced the first clinical data for HEPLISAV TM investigational hepatitis B vaccine in chronic kidney disease patients. These data will be presented in a poster session October 31, 2009 at the 47th Annual Meeting of the Infectious Disease Society of America (IDSA) in Philadelphia, Pennsylvania. Vaccinated with HEPLISAV, chronic kidney disease patients demonstrated rapid, increased protection against hepatitis B viral infection in fewer doses than patients receiving licensed vaccine. 96% of patients (n = 36) receiving 3 doses of HEPLISAV achieved seroprotection at month 7, compared to 88% of patients (n = 10) receiving 8 doses of Engerix-B. Dynavax recently began vaccinating chronic kidney disease patients with HEPLISAV in a Phase 3 registration trial.

Dynavax Technologies Corporation reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. For the quarter, the company's total revenues were $2.9 million, compared to $8.9 million reported for the third quarter in 2008. The decline in total revenues for the third quarter was primarily due to a decrease in collaboration revenue following the termination of the Merck & Co. Inc. collaboration for HEPLISAV. On a pro forma basis, the company's revenues were $3.9 million compared to $9.9 million for the same period a year ago. The net loss attributable to the company of $9.5 million, or $0.24 per share, reported for the quarter increased from the net loss attributable to the company of $5.4 million, or $0.14 per share, for the same period in 2008. The increase in net loss for third quarter is due to a decrease in collaboration revenue partially offset by a decrease in total operating expenses. Net loss was $10.7 million compared with $7.1 million for the same period a year ago. Loss from operations was $10.7 million compared with $5.8 million for the same period a year ago. For the nine months, the company's total revenues were $38.1 million, compared to $25.1 million for the same period in 2008. The increase in revenues for the nine months ended September 30, 2009 was primarily attributable to the recognition of $28.5 million of non-cash deferred revenue that was accelerated upon the termination of the Merck collaboration. On a pro forma basis, the company's revenues were $12.2 million compared to $27.9 million for the same period in 2008. The net loss attributable to the company of $0.3 million, or $0.01 per share, reported for the period significantly improved compared to the net loss attributable to the company of $23.9 million, or $0.60 per share, for the same period in 2008. The improvement in net loss for the nine months is due to the recognition of non-cash deferred revenue and a decrease in total operating expenses. Net loss was $3.4 million compared with $28.7 million for the same period a year ago. Loss from operations was $3.5 million compared with $26.0 million for the same period a year ago.